Article

CAR T-Cells for Cancer Immunotherapy – Moving Target for Industry?

By: Dr Paula Salmikangas, Advisory Board Director, Dr Niamh Kinsella, VP Early Stage Development and Paul Chamberlain Advisory Board Member

Publ. 2018-08-02

NDA’s Paula SalmikangasNiamh Kinsella and Paul Chamberlain have co-authored the article “Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?

Read the full article which discusses the product-and patient-related variables that may pose challenges for the industry and developers both from the scientific and regulatory perspective.

This article is featured in Volume 35, Issue 8, August 2018 – in the Topical Collection of Pharmaceutical Research and is currently available online.

Pharmaceutical Research is an Official Journal of the American Association of Pharmaceutical Scientists, which presents papers that describe innovative research spanning the entire spectrum of drug discovery, development, evaluation, and regulatory approval. Small drug molecules, biotechnology products including genes, peptides, proteins and vaccines, and genetically engineered cells are an integral part of papers published here.

Link to Original Article

The Authors

Dr Paula Salmikangas,
Advisory Board Director

Read More

Niamh Kinsella,
 VP Early Stage Development

Read More

Paul Chamberlain
Advisory Board Member

Read More

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World